Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name Lisocabtagene maraleucel
Trade Name Breyanzi
Synonyms JCAR 017|JCAR017|JCAR-017
Drug Descriptions

Breyanzi (lisocabtagene maraleucel) comprises equal amount of CD4+ and CD8+ autologous T lymphocytes engineered to express chimeric antigen receptors containing an anti-CD19 fragment fused to the 4-1BB (CD137) signaling domain, which may results in immune modulating and anti-tumor activities (PMID: 32888407). Breyanzi (lisocabtagene maraleucel) is FDA approved for use in patients with large B-cell lymphoma including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who are refractory to or relapsed within 12 months of first-line immunochemothrapy, or have refractory or relapsed disease after first-line immunochemothrapy and not eligible for r hematopoietic stem cell transplantation, or have relapsed or refractory disease after two or more lines of systemic therapy (FDA.gov).

CAS Registry Number NA
NCIT ID C125192


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Acalabrutinib + Lisocabtagene maraleucel Acalabrutinib Lisocabtagene maraleucel 0 1
axicabtagene ciloleucel + Lisocabtagene maraleucel + Tisagenlecleucel Lisocabtagene maraleucel Tisagenlecleucel axicabtagene ciloleucel 0 1
Cyclophosphamide + Fludarabine + Ibrutinib + Lisocabtagene maraleucel Cyclophosphamide Fludarabine Ibrutinib Lisocabtagene maraleucel 0 1
Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel Cyclophosphamide Fludarabine Lisocabtagene maraleucel 0 2
Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel + Zanubrutinib Cyclophosphamide Fludarabine Lisocabtagene maraleucel Zanubrutinib 0 1
Durvalumab + Lisocabtagene maraleucel Durvalumab Lisocabtagene maraleucel 0 1
Ibrutinib + Lisocabtagene maraleucel Ibrutinib Lisocabtagene maraleucel 0 1
Lisocabtagene maraleucel Lisocabtagene maraleucel 0 6

Additional content available in CKB BOOST